Skip to main content
AAN.com

Abstract

Objective and background Frontotemporal dementia (FTD) is a common, non-Alzheimer's dementia. Its familial occurrence has been reported, but the frequency of positive family history is unknown.
Methods We carried out a nationwide genetic-epidemiologic study of FTD in the Dutch population of 15 million people. The family history of dementia was analyzed in 74 FTD patients and 561 age- and gender-matched control subjects.
Results We found one or more first-degree relatives with dementia before age 80 in 38% (28 of 74) of FTD patients, but only in 15% (84 of 561) of control subjects. Ten percent of FTD patients had two or more first-degree relatives with dementia compared with 0.9% of the control subjects. Seven percent of FTD patients showed the ApoE4E4 genotype versus 2.3% of the control subjects. The first-degree relatives of FTD had a risk of 22% for dementia before age 80 compared with 11% in relatives of control subjects. The age of onset of dementia in affected first-degree relatives of FTD patients (60.9 ± 10.6 years) was significantly lower than among affected relatives of control subjects (72.3 ± 8.5 years). The first-degree relatives of FTD patients were 3.5 times (95% CI, 2.4 to 5.2) more at risk for developing dementia before age 80 than relatives of control subjects. The hazard ratio in the subgroup with unknown linkage to chromosome 17 was 2.4 (95% CI, 1.5 to 3.7).
Conclusion This study documents the importance of genetic factors in a proportion of FTD patients with the age at onset of dementia in first-degree relatives being 11 years earlier than in the general population.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 50Number 6June 1998
Pages: 1541-1545
PubMed: 9633692

Publication History

Published online: June 1, 1998
Published in print: June 1998

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

M. Stevens, MD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
C. M. van Duijn, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
W. Kamphorst, MD, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
P. de Knijff, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
P. Heutink, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
W. A. van Gool, MD, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
P. Scheltens, MD, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
R. Ravid, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
B. A. Oostra, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
M. F. Niermeijer, MD, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.
J. C. van Swieten, MD, PhD
From the Department of Neurology (Drs. Stevens and Swieten), University Hospital Rotterdam, The Netherlands; the Departments of Epidemiology & Biostatistics (Dr. van Duijn) and Clinical Genetics (Drs. Heutink, Oostra, and Niermeijer), Erasmus University Rotterdam; the Department of Pathology (Dr. Kamphorst) and Neurology (Dr. Scheltens), Academic Hospital Vrije Universiteit, Amsterdam; the Department of Human Genetics (Dr. de Knijf3, Sylvius Laboratory, University of Leiden; the Department of Neurology (Dr. van Gool), Academic Medical Center, Amsterdam; and The Netherlands Brain Bank (Dr. Ravid), Amsterdam, The Netherlands.

Notes

Address correspondence and reprint requests to Dr. John C. van Swieten, Department of Neurology, Dijkzigt Hospital Rotterdam, Dr. Molenwaterplein 40, 3015 GD Rotterdam, The Netherlands.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. The prevalence of frontotemporal dementia, Neurology, 58, 11, (1615-1621), (2023)./doi/10.1212/WNL.58.11.1615
    Abstract
  2. Preclinical evaluation of WVE-004, an investigational stereopure oligonucleotide for the treatment of C9orf72-associated ALS or FTD, Molecular Therapy - Nucleic Acids, 28, (558-570), (2022).https://doi.org/10.1016/j.omtn.2022.04.007
    Crossref
  3. Sex and gender differences in dementia, Sex and Gender Differences in Neurological Disease, (179-233), (2022).https://doi.org/10.1016/bs.irn.2022.07.002
    Crossref
  4. Genetic Counselling Improves the Molecular Characterisation of Dementing Disorders, Journal of Personalized Medicine, 11, 6, (474), (2021).https://doi.org/10.3390/jpm11060474
    Crossref
  5. Plasma cholesterol in Alzheimer’s disease and frontotemporal dementia, Translational Neuroscience, 11, 1, (116-123), (2020).https://doi.org/10.1515/tnsci-2020-0098
    Crossref
  6. Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure, Neurobiology of Aging, 86, (143-155), (2020).https://doi.org/10.1016/j.neurobiolaging.2019.10.015
    Crossref
  7. Linking amyotrophic lateral sclerosis and frontotemporal dementia, Diagnosis and Management in Dementia, (49-59), (2020).https://doi.org/10.1016/B978-0-12-815854-8.00004-5
    Crossref
  8. Genetic discoveries and advances in late‐onset Alzheimer’s disease, Journal of Cellular Physiology, 234, 10, (16873-16884), (2019).https://doi.org/10.1002/jcp.28372
    Crossref
  9. The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort, Journal of Alzheimer's Disease, 61, 2, (753-760), (2017).https://doi.org/10.3233/JAD-170661
    Crossref
  10. Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study, Brain, 140, 6, (1784-1791), (2017).https://doi.org/10.1093/brain/awx103
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Share article link

Share